Compare SAFE & IVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SAFE | IVA |
|---|---|---|
| Founded | 2016 | 2011 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.1B |
| IPO Year | 1999 | 2020 |
| Metric | SAFE | IVA |
|---|---|---|
| Price | $14.93 | $4.70 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 10 | 10 |
| Target Price | ★ $19.00 | $16.20 |
| AVG Volume (30 Days) | 264.1K | ★ 699.1K |
| Earning Date | 04-30-2026 | 03-30-2026 |
| Dividend Yield | ★ 4.48% | N/A |
| EPS Growth | ★ 7.43 | N/A |
| EPS | ★ 0.82 | N/A |
| Revenue | ★ $385,552,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.31 | $751.20 |
| P/E Ratio | $18.60 | ★ N/A |
| Revenue Growth | ★ 5.43 | N/A |
| 52 Week Low | $12.76 | $3.35 |
| 52 Week High | $17.45 | $7.98 |
| Indicator | SAFE | IVA |
|---|---|---|
| Relative Strength Index (RSI) | 36.79 | 55.72 |
| Support Level | $14.72 | $4.11 |
| Resistance Level | $15.55 | $4.70 |
| Average True Range (ATR) | 0.46 | 0.20 |
| MACD | -0.16 | -0.01 |
| Stochastic Oscillator | 0.00 | 62.50 |
Safehold Inc is a REIT that operates its business by acquiring, managing, and capitalizing ground leases. Ground leases are long-term contracts between the landlord (the Company) and a tenant or leaseholder. Ground leases generally represent ownership of the land underlying commercial real estate projects that are net leased by the fee owner of the land to the owners/operators of the real estate projects built thereon.
Inventiva SA is a France-based clinical-stage biopharmaceutical company focused on the development of oral small-molecule therapies for the treatment of MASH. The wholly-owned research and development facility and a team with expertise and experience in the development of compounds that target nuclear receptors, transcription factors and epigenetic modulation. Leveraging the expertise, the company is also advancing lanifibranor for the treatment of MASH and has a pipeline of earlier-stage therapeutic programs in oncology. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France.